Help us improve this page by adding information.
Visit our Writing Guide or this topic page for additional help.
Visit our Writing Guide or this topic page for additional help.
Timeline
Funding rounds
People
Name
Role
LinkedIn
Dat Bich Le
Employee
Eric Epstein
Employee
Melissa S. Whipkey
Employee
Oteng Amoa
Employee
Further reading
Title
Author
Link
Type
Date
Documentaries, videos and podcasts
Title
Date
Link
Companies
Company
CEO
Location
Products/Services
News
Title
Author
Date
Publisher
Description
BioSpace
April 14, 2021
BioSpace
aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, and Lonza today announced that the companies have entered into an agreement for the manufacture of ATYR2810, aTyr's monoclonal antibody targeting Neuropilin-2 (NRP2) that is currently in preclinical development for cancer.
Reuters Editorial
June 5, 2020
IN
Swiss contract drug manufacturer Lonza Group on Friday named Roche manager Pierre-Alain Ruffieux as its new chief executive, effective Nov. 1, underscoring its focus on its fast-growing pharmaceuticals business.
Is a
Company attributes
Location
Company status
Active
B2X
Crunchbase
Legal classification
Investors
DUNS Number
480667059
Founded date
January 1, 1897
Total funding amount (USD)
2,014,050
Latest funding round date
June 20, 2007
Stock exchange
Former CEO
Categories
Related Topics
Contributors
- 1
Aime Anne Nisay
QA Engineer of web and mobile applications - 2
Dawson Sewell
Writing about startups. - 3
Amy Tomlinson Gayle
QA Editor based in Austin, TX - 4
Jude Gomila
Founder and CEO of Golden, Entrepreneur. Investor in 200+ companies. Cantabrigian (Gonville and Caius). Interested in the Universe. - 5
Aleksander Holm
Interested in understanding the world we live in. - 6
Melanie Manipula
Helping organize knowledge. - 7
Jason D. Rowley
Former Data Acquisition Lead @ Golden (Recursion Inc.). Excited about open knowledge and pulling the future forward.